ERBB2 and breast carcinoma: A retrospective study on neoadjuvant therapy for HER2+ breast cancer reported that patients treated with a regimen in which trastuzumab was administered concurrently with anthracyclines for 24 weeks (trastuzumab and paclitaxel for 12 weeks followed by trastuzumab and FEC for 12 weeks) achieved a higher pCR rate compared to that observed in patients treated with 18 weeks of trastuzumab in association with a nonanthracycline-based regimen, docetaxel and carboplatin (60.6 vs 43.3 %; P = 0.016) (Bayraktar et al. 2012).